Glaukos Co. (NYSE:GKOS) Receives $145.92 Average PT from Analysts

Shares of Glaukos Co. (NYSE:GKOS) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $145.92.

A number of research firms have issued reports on GKOS. Stephens raised Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group initiated coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock. StockNews.com raised shares of Glaukos from a “sell” rating to a “hold” rating in a research report on Monday, October 21st. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Monday, December 2nd. Finally, Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,603 shares of company stock valued at $2,605,678. 6.40% of the stock is currently owned by company insiders.

Institutional Trading of Glaukos

A number of hedge funds and other institutional investors have recently made changes to their positions in GKOS. Values First Advisors Inc. bought a new stake in shares of Glaukos during the third quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd boosted its position in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 860 shares during the last quarter. KBC Group NV increased its stake in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the period. Brighton Jones LLC bought a new stake in shares of Glaukos during the second quarter worth $208,000. Finally, EWA LLC bought a new stake in shares of Glaukos during the third quarter worth $209,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Trading Down 1.0 %

NYSE:GKOS opened at $151.16 on Wednesday. The company’s 50 day moving average is $140.18 and its 200-day moving average is $129.42. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 12 month low of $74.75 and a 12 month high of $153.50. The firm has a market cap of $8.33 billion, a price-to-earnings ratio of -50.05 and a beta of 1.03.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million for the quarter, compared to the consensus estimate of $91.50 million. During the same quarter last year, the firm posted ($0.50) EPS. The business’s quarterly revenue was up 23.9% on a year-over-year basis. Equities analysts anticipate that Glaukos will post -1.89 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.